Abdominal aortic aneurysm medical therapy

Revision as of 02:56, 29 October 2012 by Aarti Narayan (talk | contribs)
Jump to navigation Jump to search

Abdominal Aortic Aneurysm Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Abdominal Aortic Aneurysm from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Abdominal aortic aneurysm medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Abdominal aortic aneurysm medical therapy

CDC on Abdominal aortic aneurysm medical therapy

Abdominal aortic aneurysm medical therapy in the news

Blogs on Abdominal aortic aneurysm medical therapy

Directions to Hospitals Treating Abdominal aortic aneurysm medical therapy

Risk calculators and risk factors for Abdominal aortic aneurysm medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2] Aarti Narayan, M.B.B.S [3]

Overview

Risk factor modification including smoking cessation, management of hypertension, and lipid lowering are essential in reducing the risk of development and the rate of progression of abdominal aortic aneurysms.

Medical Therapy

Management

  • Risk factor modification
  • ACEI, beta blockers, statins, aspirin, antibiotics for possible chlamydia infection
  • Assess for coronary, carotid and peripheral vascular disease
  • Surveillance:
    • 4 to 5.4 cm - monitor every 6 to 12 months
    • 3 to 4 cm - monitor every 2 to 3 years

Acute pharmacotherapies

  • Antimetalloproteases such as doxycycline and roxithromycin may halt aneurysm expansion
  • Similarly, non-steriod anti inflammatory drugs have shown to be beneficial in small studies
  • Beta blockers have numerous benefits in patients with cardiovascular disease
    • Reduce aortic complications in patients with Marfan syndrome
    • Slow progression of AAAs in hypertensive patients
    • In the absence of other indications for beta blockers, the evidence is insufficient to recommend using them routinely for the sole purpose of slowing atherosclerotic aneurysm growth

References

Template:WH Template:WS